New hope for tough lung cancers: drug combo trial launches

NCT ID NCT05117242

Ongoing Disease control Sponsor: Genmab Source: ClinicalTrials.gov ↗

First seen Nov 06, 2025 · Last updated May 12, 2026 · Updated 22 times

Summary

This trial tests a new drug called acasunlimab, either alone or combined with the cancer drug pembrolizumab, for people with advanced non-small cell lung cancer that has returned or stopped responding to standard treatments. About 125 adults will receive the drugs intravenously every 3 or 6 weeks for around 6 months. The goal is to see if the combination shrinks tumors better than acasunlimab alone.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Azienda Ospedaliera Universitaria Policlinico G Rodolico San Marco

Catania, Italy
Cancer & Hematology Centers of Western Michigan CHCWM P.C.

Grand Rapids, Michigan, 49503, United States
Centro Clinico Champalimaud

Lisbon, Portugal
Centro Hospitalar Universitário do Porto - Hospital de Santo Antonio

Porto, Portugal
Cheltenham General Hospital

Cheltenham, United Kingdom
Clinica Universidad de Navarra

Pamplona, Spain
Clinica Universidad de Navarra CUN

Madrid, Spain
Department of Internal Medicine II

Regensburg, Germany
Erasmus MC

Rotterdam, Netherlands
Florida Cancer Center

St. Petersburg, Florida, 33705, United States
Florida Cancer Specialists - FCS South

Fort Myers, Florida, 33901, United States
Fundacion Instituto Valenciano de Oncologia

Valencia, Spain
Gustave Roussy

Villejuif, France
Henry Ford Cancer Institute

Detroit, Michigan, 48202, United States
Hopital Charles Nicolle Chu Rouen

Rouen, France
Hopital Morvan CHU de Brest

Brest, France
Hopital dInstruction Des Armees Begin

Saint-Mandé, France
Hospital Universitari Vall dHebron

Barcelona, Spain
Hospital Universitario 12 de Octubre

Madrid, Spain
Hospital Universitario Fundacion Jimenez Diaz

Madrid, Spain
Hospital Universitario Virgen de la Victoria

Málaga, Spain
Hôpital Foch

Suresnes, France
IFO Regina Elena

Roma, Italy
IRCCS Istituto Europeo di Oncologia

Milan, Italy
Institut Bergonie

Bordeaux, France
Institut de Cancerologie Strasbourg Europe (ICANS)

Strasbourg, France
LKI Lungenfachklinik Immenhausen

Immenhausen, Germany
La Maddalena SPA

Palermo, Italy
Leids Universitair Medisch Centrum

Leiden, Netherlands
MD Anderson Cancer Center

Madrid, Spain
Maria Sklodowska-Curie National Research Institute of Oncology

Warsaw, Poland
Med.Hochschule Hannover Klinik für Pneumologie

Hanover, Germany
Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States
Netherlands Cancer Institute

Amsterdam, Netherlands
Samodzielny Publiczny Zespol Gruzlicy i Chorob Pluc

Olsztyn, Poland
St. Joseph Heritage Healthcare

Santa Rosa, California, 95403, United States
The Christie Hospital

Manchester, United Kingdom
UOC Oncoematologia AOU L.Vanvitelli

Naples, Italy
Universitatsklinik Giessen und Marburg Standort Giessen

Hessen, Germany
VU University Medical Center

Amsterdam, Netherlands

Conditions

Explore the condition pages connected to this study.

NON SMALL CELL LUNG CANCER METASTATIC